Drug Trial Radar · NCT07737743
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
344
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Feb 19, 2029
Study completion Mar 19, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection for Phase 3.
Conditions
- Sjögren's Disease
Interventions
DDY391Drug
DDY391 dose level 1 DDY391 dose level 2 DDY391 dose level 3
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and B: Change from baseline in ESSDAI scoreTime frame: Baseline, Week 24
- Part C: Change from baseline in ESSPRITime frame: Baseline, Week 24
Locations
31 sites in 9 countries. Site status is shown where the registry gives one.
Arizona Arthritis and Rheumatology Associates PLLC
Avondale, Arizona · Recruiting
Clinical Res Of W Florida
Clearwater, Florida · Recruiting
Clinical Research of West Florida Inc
Tampa, Florida · Recruiting
Chicago Clinical Research Inst
Chicago, Illinois · Recruiting
Willow Rheumatology Wellness
Willowbrook, Illinois · Recruiting
RAO Research LLC
Oklahoma City, Oklahoma · Recruiting
Altoona Center for Clin Res
Duncansville, Pennsylvania · Recruiting
Rheumatology Specialty Center - Willow Grove Office
Willow Grove, Pennsylvania · Recruiting
Shelby Research LLC
Memphis, Tennessee · Recruiting
Stryde Research-Allen Arthritis
Allen, Texas · Recruiting
Novel Research LLC
Bellaire, Texas · Recruiting
Arthritis Care of Texas
Corpus Christi, Texas · Recruiting
Novartis Investigative Site
Southport, Queensland, Australia · Recruiting
Novartis Investigative Site
Nedlands, Western Australia, Australia · Recruiting
Novartis Investigative Site
Rimouski, Quebec, Canada · Recruiting
Novartis Investigative Site
Sherbrooke, Quebec, Canada · Recruiting
Novartis Investigative Site
Trois-Rivières, Quebec, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Hefei, Anhui, China · Recruiting
Novartis Investigative Site
Nanjing, Jiangsu, China · Recruiting
Novartis Investigative Site
Taiyuan, Shanxi, China · Recruiting
Novartis Investigative Site
Bogota, Cundinamarca, Colombia · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Kaposvár, Hungary · Recruiting
Novartis Investigative Site
Kfar Saba, Israel · Recruiting
Novartis Investigative Site
Petah Tikva, Israel · Recruiting
Novartis Investigative Site
Ramat Gan, Israel · Recruiting
Novartis Investigative Site
Tel Aviv, Israel · Recruiting
Novartis Investigative Site
Tsrifin, Israel · Recruiting
Novartis Investigative Site
Groningen, Provincie Groningen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.